Endocrinol Metab > Volume 26(3); 2011 > Article
Endocrinology and Metabolism 2011;26(3):218-224.
DOI: https://doi.org/10.3803/EnM.2011.26.3.218    Published online September 1, 2011.
Effect of Omega-3 Fatty Acids on Low Density Lipoprotein Subfraction, Adiponectin and Apolipoprotein B in Type 2 Diabetic Patients.
Haejung Jun, Junghae Ko, Hyesook Jung, Changshin Yoon, Taekyoon Kim, Minjeong Kwon, Soonhee Lee, Jihye Suk, Mikyung Kim, Dukkyu Kim, Jeong Hyun Park
1Molecular Therapy Lab, Paik Memorial Institute for Clinical Research, Busan, Korea. pjhdoc@chol.com
2Department of Internal Medicine, College of Medicine, Inje University, Busan, Korea.
3Department of Internal Medicine, Maryknoll Medical Center, Busan, Korea.
4Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Abstract
BACKGROUND
Omega-3 fatty acids derived from fish oil have been reported to exert a beneficial effect on reducing cardiovascular disease. Reports about their mechanism have generated several interesting findings, including a change in small dense low density lipoprotein (sdLDL) cholesterol proportion, adiponectin, and apolipoprotein B (apoB), in addition to changes in the lipid profile. The principal objective of our study was to evaluate the effects of omega-3 fatty acids on plasma sdLDL, adiponectin, apoB100, and B48 in type 2 diabetic patients with hypertriglyceridemia. METHODS: We randomized 28 type 2 diabetic patients in a placebo-controlled, double-blind trial to receive either omega-3 fatty acids or placebo, both administered at a dose of 4 g daily for 12 weeks. LDL subfractions prior to and after treatment were separated via low-speed ultracentrifugation and analyzed via immunoelectrophoresis. Adiponectin, apoB100, and B48 levels were measured using an ELISA kit. RESULTS: sdLDL proportions were reduced in the omega-3 fatty acids group by 11% after 12 weeks of treatment (n = 17, P = 0.001), and were reduced by 4% in the control group (n = 11, P = 0.096). The patients receiving the omega-3 fatty acids evidenced a significant reduction in the levels of triglyceride (P = 0.001), apoB100, and B48 after 12 weeks (P = 0.038 and P = 0.009, respectively) relative to the baseline. Omega-3 fatty acids supplementation increased fasting blood glucose (P = 0.011), but the levels of HbA1c in each group did not change to a statistically significance degree. The adiponectin value was not reduced in the omega-3 fatty acids group (P = 0.133); by way of contrast, the placebo group evidenced a significant reduction in adiponectin value after 12 weeks (P = 0.002). CONCLUSION: Omega-3 fatty acid treatment proved effective in the reduction of atherogenic sdLDL and apoB in type 2 diabetic patients (Clinical trials reg. no. NCT 00758927, clinicaltrials.gov).
Key Words: Adiponectin, Apolipoprotein B48, Apolipoprotein B100, Omega-3 fatty acids, Small dense LDL cholesterol, Type 2 Diabetes mellitus


Editorial Office
101-2503, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-716-2428    Fax: +82-2-714-5103    E-mail: journal@endocrinology.or.kr                

Copyright © 2021 by Korean Endocrine Society.

Developed in M2PI

Close layer
prev next